Highlights

  • Ceretas Limited (ASX:CTS) has reached a key milestone in its dementia-focused technology development program.
  • Completion of the milestone is tied to release of a further funding installment from Brandon BioCatalyst.
  • Two separate hardware and software prototypes have reportedly reached functional status.
  • The update builds on a grant secured in mid-2025 through a federally supported medical technology initiative.

Ceretas Limited (ASX:CTS) has advised the market that it has completed Milestone 3 under its CUREator+ development initiative, a program directed at supporting technology aimed at dementia and cognitive decline. The milestone, confirmed in an ASX announcement dated 16 September 2026, is linked to the release of a further funding installment from Brandon BioCatalyst and follows the delivery of two separate prototype components developed as part of the company's broader technology program.

Milestone Achievement and Funding

The completion of Milestone 3 unlocks the final funding installment of $692,578 from Brandon BioCatalyst, the organisation administering the program under which Ceretas has been operating. This final Tranche represents the conclusion of the staged funding structure associated with the CUREator+ initiative, with each milestone within the program tied to specific development outcomes that must be achieved before further funds are released. The completion of this stage indicates that Ceretas has satisfied the criteria set for this phase of the program, allowing the company to proceed with its planned development activities using the newly available capital.

Technology Development

As part of Milestone 3, Ceretas delivered fully functional prototypes for two distinct components of its technology program. The first is an in-house developed image-guided neuronavigation (IGN) software system, designed to precisely target certain regions of the brain. According to the company, the proprietary IGN system reduces the number of required operators from two to one, a change the company says enhances operational efficiency while lowering Manufacturing expenses. The second prototype is a lift assist device, developed through a collaboration with Planet Innovation. Together, these two components form the core hardware and software elements of the broader system Ceretas is developing for use in dementia and cognitive decline-related applications.

Program Background

The CUREator+ program in which Ceretas is participating traces back to July 2025, when the company received a $2.4 million grant through Australia's Medical Research Future Fund BioMedTech Incubator initiative. The program is administered by Brandon BioCatalyst in conjunction with ANDHealth and Dementia Australia, reflecting a collaborative structure involving multiple organisations focused on advancing medical technology development in Australia. The BioMedTech Incubator initiative is designed to support the progression of early-stage medical technologies through structured, milestone-based funding, of which the recently completed Milestone 3 forms a part.

The involvement of Dementia Australia alongside Brandon BioCatalyst and ANDHealth underlines the focus of the program on translating early-stage research into practical technologies intended for use in dementia and cognitive decline settings. Programs of this nature typically release funding in stages tied to defined development outcomes, a structure intended to provide oversight over how public funding is applied across the life of a project. The completion of Milestone 3, and the associated release of the final funding installment, represents the conclusion of this particular staged arrangement for Ceretas within the CUREator+ program.

Key Takeaways

The completion of Milestone 3 marks a further step in Ceretas Limited's development pathway under the CUREator+ program, with the delivery of two functional prototypes and the unlocking of the final funding installment from Brandon BioCatalyst. The update reflects continued progress within a government-supported medical technology initiative directed at dementia and cognitive decline, with the company's next steps expected to build on the technology foundations established during this phase.